In this study, a core-shell type polypeptide-based lipid nanocapsule was developed to
enhance anticancer efficacy of erlotinib in non-small cell lung cancers. Mean particle size of …

Core–shell type lipid–polymer hybrid nanoparticles (CSLPHNPs) have emerged as a
multifunctional drug delivery platform. The delivery system combines mechanical …

Purpose Cisplatin (CDDP) and etoposide (Etp) are recommended first-line therapy for lung
cancer. Nanostructured lipid carriers (NLCs) are engineered to deliver drugs for lung cancer …

Purpose Lung cancer is the leading cause of cancer-related deaths. The aim of this study
was to design solid lipid core nanocapsules (SLCN) comprising a solid lipid core and a …

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in
China. This study aimed to develop a hyaluronic acid (HA) decorated, pH sensitive lipid …

Cancer treatments are always associated with various challenges, and scientists are
constantly trying to find new therapies and methods. Erlotinib (ELT) is a well-known …

Lung cancer is a formidable challenge in clinical practice owing to its metastatic nature and
resistance to conventional treatments. The codelivery of anticancer agents offers a potential …

The aim of this study to develop galactosylated erlotinib liposomes for treatment of lung
cancer. The liposomes were prepared by using solvent evaporation method. Various …

Gefitinib (GEB) is one of the drugs used for patients with epidermal growth factor receptor
(EGFR)-positive mutations in non-small cell lung cancer (NSCLC). However, application of …

Gefitinib (GEF) is utilized in clinical settings for the treatment of metastatic lung cancer.
However, premature drug release from nanoparticles in vivo increases the exposure of …